Rojkjaer Lisa 4
4 · RIGEL PHARMACEUTICALS INC · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Rigel Pharmaceuticals EVP Lisa Rojkjaer Receives RSU Award
What Happened
Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals (RIGL), was granted 18,894 restricted stock units (RSUs) on February 17, 2026. The Form 4 reports the acquisition price as $0.00 (transaction code A), so no cash changed hands at grant. The RSUs will convert to common stock as they vest.
Key Details
- Transaction date: 2026-02-17; Form 4 filed 2026-02-19 (timely filing).
- Transaction type/code: Award/Grant (A).
- Shares awarded: 18,894 RSUs; reported acquisition price $0.00; reported total $0.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote (F1): RSUs vest quarterly over three years, with the first quarterly vesting on March 31, 2026.
Context
This was a compensation grant rather than an open-market purchase or sale. RSU awards are common executive compensation and do not result in issued shares until they vest; they therefore do not necessarily indicate immediate insider sentiment about the stock.
Insider Transaction Report
Form 4
Rojkjaer Lisa
EVP, Chief Medical Officer
Transactions
- Award
Common Stock
[F1]2026-02-17+18,894→ 34,853 total
Footnotes (1)
- [F1]The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.
Signature
/s/ Raymond Furey (Attorney-in-Fact)|2026-02-19